

ASX Release
9th July 2015

RHS to facilitate training in PGS (Pre-implantation Genetic Screening) for IVF providers with EmbryoCollect™

Highlights

- RHS to provide training in PGS using EmbryoCollect™ for international clinics
- Increased Australian interest in RHS' PGS service provision
- Further sales of EmbryoCollect™ through distributor relationships

Adelaide, 9th July 2015: Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to provide a brief update for investors following the recent European Society for Human Reproduction and Embryology (ESHRE) conference held in Lisbon mid-June 2015. This meeting is the largest international forum relevant to the *in-vitro* fertilisation (IVF) industry and RHS exhibited and provided product demonstrations to a large number of interested distributors and clinics.

Following on from the ESHRE meeting, further industry interest has culminated in RHS agreeing to facilitate training programmes in the use of EmbryoCollect™ in PGS (Pre-implantation Genetic Screening) for IVF clinics from various jurisdictions. These are being scheduled for the near term in Adelaide. RHS' CEO Dr. Michelle Fraser commented “RHS is currently hosting the Morula IVF clinic from Indonesia as this clinic gains confidence and experience in microarray technology. Given the high level of interest in EmbryoCollect™, we are also scheduling training for other clinics from August onwards. The level of advice and training depends on previous scientific exposure to PGS technology and for some clinics the training will simply be a kit familiarisation exercise. The tailored offering of variable training requirements is quite consistent with our planning for customer support activities to further drive uptake and sales.”

As announced on the 2nd June 2015, RHS has a collaborative agreement with flinders**fertility** to provide a PGS service for IVF patients. This unique arrangement with an Australian IVF provider to provide PGS on a fee-for-service basis using RHS' lead product EmbryoCollect™ has created significant IVF industry interest. Dr Fraser noted “RHS is ready for the commencement of the flinders**fertility** PGS service in August 2015 as planned. The PGS service provision is an exciting opportunity and there are ongoing discussions with other Australian IVF providers for such a PGS service.”

The ESHRE conference was also attended by current and prospective commercial distributors of EmbryoCollect™. These distributors are working with RHS to introduce PGS with EmbryoCollect™ in their territory and small numbers of kits sales have already been recorded for this quarter.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9380
michelle.fraser@rhsc.com.au

Dr David Brookes
Chairman
Tel: (+61 8) 8152 9380
david.brookes@rhsc.com.au

About Reproductive Health Science

Reproductive Health Science is an advanced biotech company that has successfully developed a lead product EmbryoCollect™, a test to assess embryos for chromosomal abnormalities prior to implantation as part of an In-Vitro Fertilisation (IVF) cycle. The two component DNA amplification and quantitative microarray system has an immediate application to improve the success rate of IVF by assisting in the identification of embryos with the correct number of chromosomes. Launched in 2014, EmbryoCollect™ contains reagents for 20 tests at a list price of AUD \$3,600 per kit. RHS' assumption for business modelling purposes, based on IVF experience, is that there are 4 embryos per cycle.

Reproductive Health Science Ltd.
ACN 010 126 708
ASX: RHS

Issued Capital
51.13 million shares
7.33 million options

Registered Office
Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors
Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Donald Stephens
Dr Michelle Fraser (CEO)

**Finance Officer
& Company Secretary**
Raymond Ridge